MRK vs DXCM
By Alex · Tickerpine
Merck & Co., Inc. vs DexCom, Inc., side by side — the numbers that matter, in plain English. No “winner” hype; you decide.
| Metric | MRK | DXCM |
|---|---|---|
| Price | $128.66 | $70.14 |
| Market cap | $317.77B | $27.07B |
| P/E ratio | 36.2 | 30.1 |
| ROE | 18.94% | 35.62% |
| Profit margin | 13.59% | 19.31% |
| Revenue growth | 4.90% | 15.00% |
| Dividend yield | 2.64% | — |
| Beta | 0.22 | 1.44 |
Green = the more favorable figure for that metric (lower P/E, higher ROE, margin, growth and yield). Not a recommendation.
MRK vs DXCM in plain English
- MRK is the bigger company — about 11.7× the market cap of DXCM.
- DXCM is cheaper on earnings (P/E 30.1 vs 36.2).
- DXCM earns a higher return on equity (36% vs 19%).
- DXCM is growing revenue faster (15% vs 5%).
- MRK pays a dividend (2.64%) while the other effectively doesn't.
How would $1,000 have done in each?
MRK return calculator
See what $1,000 in Merck & Co., Inc. would be worth today.
DXCM return calculator
See what $1,000 in DexCom, Inc. would be worth today.
Figures from public market data, may be delayed. Comparison is informational only — not investment advice.